1-3 of 3
Kenneth Attie
Close
Sort by
Journal Articles

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Biree Andemariam, Timothy Mant, Perla Eleftheriou, Sanne Lugthart, Lanetta Bronté-Hall, Filipa Barroso, Gershwin Blyden, James Mason, Constance M Barysauskas, Joseph Yen, Karen Tang, Rahul Ballal, Kenneth Attie
Journal: Blood
Blood (2021) 138 (Supplement 1): 2046.
https://doi.org/10.1182/blood-2021-149536
Published: 2021
Journal Articles

An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion

Rami S Komrokji, MD, Guillermo Garcia-Manero, MD, Lionel Ades, MD PhD, Abderrahmane Laadem, MD, Bond Vo, PharmD, Thomas Prebet, MD PhD, Aspasia Stamatoullas, MD, Thomas Boyd, MD, Jacques Delaunay, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS, Odile Beyne-Rauzy, MD PhD, Jun Zou, MS, Kenneth Attie, MD, Matthew L. Sherman, MD, Pierre Fenaux, MD PhD, Alan F. List, MD
Journal: Blood
Blood (2014) 124 (21): 3251.
https://doi.org/10.1182/blood.V124.21.3251.3251
Published: 2014
Journal Articles

A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results

Maria-Domenica Cappellini, MD, John Porter, MD, Raffaella Origa, MD, Gian Luca Forni, MD, Adberrahmane Laadem, MD, Frédéric Galacteros, MD PhD, Dimana Miteva, PhD, Victoria Sung, PhD, Rajesh Chopra, MD, Jean-Benoît Arlet, MD, PhD, Jean-Antoine Ribeil, MD, PhD, Kenneth Klesczewski, PhD, Kenneth Attie, MD, Maciej Garbowski, MD, Olivier Hermine, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3448.
https://doi.org/10.1182/blood.V122.21.3448.3448
Published: 2013